Merck & Co., Inc.'s earnings call highlights several promising developments that could positively impact its stock in the short term. The anticipated first approval for luspatercept, with both U.S. and EU regulatory filings in progress, represents a significant milestone for Acceleron and its partner Celgene. The priority review from the FDA for beta-thalassemia and strong pipeline advancement in multiple disease areas, including neuromuscular and pulmonary diseases, indicate robust near-term growth prospects. The company's optimism in scenarios of expanding luspatercept's indications and a well-positioned financial outlook further bolster confidence in its stock performance.

[1]